On October 17, 2023, the clinical trial project of "Phase Ib/II Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ST-1898 Tablets in Patients with Non-surgically Resectable or Metastatic Melanoma" was successfully initiated at Beijing Cancer Hospital.

 

Through translational medicine research, ST-1898 tablets have demonstrated good tumor inhibitory effects in preclinical animal models of melanoma. This collaboration with Prof. Guo Jun's team at Beijing Cancer Hospital, following the clinical study of kidney cancer, aims to further evaluate the efficacy and safety of ST-1898 tablets in patients with melanoma (cutaneous, mucosal, limbic, and ocular uveal melanoma) after the failure of standard treatment. It is expected that ST-1898 Tablets will achieve positive trial results in melanoma clinical trials and provide better clinical solutions for domestic melanoma patients as early as possible.

 

About ST-1989 Tablets

ST-1898 Tablet is a small molecule multi-target tyrosine kinase inhibitor independently developed by Scitech Pharma through its proprietary AI drug design platform (SigmaHit^®) and with global intellectual property rights, capable of inhibiting c-MET, VEGFR-2, PDGFRa, RET, c-KIT, TRK-A, TRK-B, AXL and other targets. The test drug can highly inhibit targets related to tumorigenesis, development and metastasis through targeted design against multiple targets, thus inhibiting multiple signaling pathways, directly and indirectly inhibiting tumor cell growth and migration, promoting apoptosis, and inhibiting tumor growth and metastasis through combined action and synergistic mechanisms.

 

ST-1898 Tablet received IND approval from National Medical Products Administration (NMPA) in July 2020. The Phase I clinical trial of the project was completed in Shanghai East Hospital, a dose escalation study in subjects with solid tumors who had failed multiple lines of treatment, with the highest dose escalated to 180 mg. No DLT occurred in any of the six subjects at this dose, and remission of tumor lesions was observed in different dose groups, which represents the study has achieved the expected results.

 

In the Phase Ib/II clinical trial of ST-1898 tablets for the treatment of advanced renal cell carcinoma, which is currently underway at Beijing Cancer Hospital, ST-1898 tablets showed good safety and tolerability, and initially verified its significant tumor shrinkage effect. In the future, Scitech Pharma will carry out more clinical studies on more indications to provide better treatment options for more tumor patients.

Scitech Pharma